Piper Sandler Maintains Overweight on TransMedics Gr, Maintains $120 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on TransMedics Group (NASDAQ:TMDX) with a $120 price target.
June 21, 2024 | 5:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on TransMedics Group (NASDAQ:TMDX) with a $120 price target.
The reaffirmation of an Overweight rating and a $120 price target by a reputable analyst is likely to positively impact investor sentiment and could lead to a short-term increase in TMDX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100